The DOI matches its Crossref record; 33 of the 35 references it cites were found in a registry or an index.
Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA
Open accessAbstract
DNA and RNA stimulate the mammalian innate immune system through activation of Toll-like receptors (TLRs). DNA containing methylated CpG motifs, however, is not stimulatory. Selected nucleosides in naturally occurring RNA are also methylated or otherwise modified, but the immunomodulatory effects of these alterations remain untested. We show that RNA signals through human TLR3, TLR7, and TLR8, but incorporation of modified nucleosides m5C, m6A, m5U, s2U, or pseudouridine ablates activity. Dendritic cells (DCs) exposed to such modified RNA express significantly less cytokines and activation markers than those treated with unmodified RNA. DCs and TLR-expressing cells are potently activated by bacterial and mitochondrial RNA, but not by mammalian total RNA, which is abundant in modified nucleosides. We conclude that nucleoside modifications suppress the potential of RNA to activate DCs. The innate immune system may therefore detect RNA lacking nucleoside modification as a means of selectively responding to bacteria or necrotic tissue.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“which is widely believed to be critical to the recent success of mRNA vaccines1,2,10,37,38”
From Algorithm for optimized mRNA design improves stability and immunogenicity (2023) · cites this paper as [37]
In the citing paper
“Modifications to the spike protein are intended to reduce the innate immune response by inhibiting proinflammatory cytokines, while at the same time, the lipid nanoparticle vehicle/EV for the mRNA acts as an adjuvant to enhance the immune response. 194-196”
From COVID-19, Myocarditis and Pericarditis (2023) · cites this paper as [194]
In the citing paper
“In general, in vitro transcribed mRNA has the risk of triggering various pattern recognition receptors in the endosome (e.g., TLR7/8) or the cytoplasm (e.g., RIG-I), which lead to an anti-viral response, followed by a shutdown of translation that can lower expression of the mRNA-encoded protein.25”
From Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines (2017) · cites this paper as [25]
In the citing paper
“Transferring this concept to in vitro transcribed mRNA, for instance, pseudouridine-containing mRNAs reduced activation of known RNA sensors substantially.”
From Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals (2015) · cites this paper as [20]
In the citing paper
“Obviously, cytokine secretion by RNA-transfected cells strongly correlated with the extent of nucleoside modifications.”
From Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals (2015) · cites this paper as [20]
In the citing paper
“In addition, nucleoside modifications are well known to limit or even inhibit RNA sensor engagement.20,21,22”
From Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals (2015) · cites this paper as [20]
In the citing paper
“Others strategies aim to impair the PRR recognition of IVT mRNA with the use of modified nucleosides,16 uridine depletion in the coding sequence,17 or dephosphorylation of 5′PPP mRNAs.18”
From Combining an optimized mRNA template with a double purification process allows strong expression of in vitro transcribed mRNA (2021) · cites this paper as [16]
In the citing paper
“In particular, we focused on ψ and m1ψ, since these substitutions for U have been widely adopted for mRNA therapeutics and vaccines due to improved in-cell translation and to better control of innate immune responses2,3,8,67 through avoidance of recognition by cellular toll-like receptors (TLR7 and TLR8)68, RIG‑I, and PKR69–71.”
From Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics (2022) · cites this paper as [70]
In the citing paper
“Studies have found that replacing original nucleosides with m6A and s2U inhibits activation of TLR3, whereas activation of TLR7 and TLR8 is blocked when using ψ, 5-methyluridine (m5U), m6A, and s2U, thereby inhibiting the innate immune responses and improving protein translation efficiency.81,159,171”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [81]
In the citing paper
“Nucleoside-modified mRNA can reduce the activation of TLRs, retinoic acid-inducible gene I (RIG-I), protein kinase R (PKR), and 2′-5′-oligoadenylate synthetase (OAS). Additionally, nucleoside modification increases translation activity and resistance against RNase L-mediated degradation.54,81,173–176”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [81]
In the citing paper
“To avoid this, Karikó and colleagues found that adding modified nucleosides during IVT of mRNA can significantly reduce the host inflammatory response without affecting protein expression.81,159”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [81]
In the citing paper
“However, the incorporation of modified nucleosides into mRNA can significantly improve the biological stability and translational capacity of the mRNA while decreasing the innate immune response.36, 37, 38”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [36]
In the citing paper
“not only viral RNA, but also endogenous mRNA associated with apoptotic cells as well as in vitro transcribed (IVT) mRNA could bind and activate TLR3, TLR7 and TLR8 [4,5]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [5]
In the citing paper
“the many modifications observed in natural mRNA are in fact a way to avoid immune recognition, allowing the immune system to distinguish self from non-self RNA [5]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [5]
In the citing paper
“Chemical modifications of specific IVT mRNA nucleotides, such as pseudouridine (ψ) and N1-methylpseudouridine (m1ψ), can reduce innate immune sensing of exogenous mRNA translation2,4,7,182.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [182]
In the citing paper
“In 2004, Karikó and colleagues observed, while exposing ex vivo human DCs to mRNA from different sources, that these cells tolerated mammalian mRNA, while strong inflammatory cytokine responses were detected upon the delivery of mRNA derived from bacteria, necrotic mammalian cells and IVT mRNA [39,40].”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [39]
Citations
Cites
A Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491 · cited 3×
“To determine whether m5C and m6A evidence, first that bacterial RNA transfected to 293-exert a dominant stimulatory effect, transcripts with hTLR9 did not induce IL-8 secretion (Figure 2C) and m6A/ Ψ double modification were tested and found to second that LPS and unmethylated DNA (CpG ODN), be nonstimulatory, whereas…”
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
Alexopoulou, L., Holt, A. C., Medzhitov, R., & Flavell, R. A. (2001) · Nature · doi:10.1038/35099560 · Cited by 6,129
Toll-like receptors and innate immunity
Medzhitov, R. (2001) · Nature Reviews Immunology · doi:10.1038/35100529 · Cited by 4,308
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004) · Science · doi:10.1126/science.1093616 · Cited by 3,444
Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis
Wang, T., Town, T., Alexopoulou, L., Anderson, J. F., Fikrig, E., & Flavell, R. A. (2004) · Nature Medicine · doi:10.1038/nm1140 · Cited by 1,142
mRNA is an endogenous ligand for toll-like receptor 3
Karikó, K., Ni, H., Capodici, J., Lamphier, M., & Weissman, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310175200 · Cited by 1,062
Self-citationHuman TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848
Jurk, M., Heil, F., Vollmer, J., Schetter, C., Krieg, A. M., Wagner, H., Lipford, G., & Bauer, S. (2002) · Nature Immunology · doi:10.1038/ni0602-499 · Cited by 838
Subcellular Localization of Toll-Like Receptor 3 in Human Dendritic Cells
Matsumoto, M., Funami, K., Tanabe, M., Oshiumi, H., Shingai, M., Seto, Y., Yamamoto, A., & Seya, T. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.6.3154 · Cited by 723
Santini, S. M., Lapenta, C., Logozzi, M., Parlato, S., Spada, M., Pucchio, T. D., & Belardelli, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.10.1777 · Cited by 644
Flagged first, then by citations
2 of the 35 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–200 of 1,004
Mitochondrial Damage-Associated Molecular Patterns: From Inflammatory Signaling to Human Diseases
Grazioli, S., & Pugin, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00832 · Cited by 429
The challenge and prospect of mRNA therapeutics landscape
Weng, Y., Li, C., Yang, T., Hu, B., Zhang, M., Guo, S., Xiao, H., Liang, X.-J., & Huang, Y. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107534 · Cited by 417
TLR13 Recognizes Bacterial 23 S rRNA Devoid of Erythromycin Resistance–Forming Modification
Oldenburg, M., Krüger, A., Ferstl, R., Kaufmann, A., Nees, G., Sigmund, A., Bathke, B., Lauterbach, H., Suter, M., Dreher, S., et al. (2012) · Science · doi:10.1126/science.1220363 · Cited by 405
RNA modifications: importance in immune cell biology and related diseases
Cui, L., Ma, R., Cai, J., Guo, C., Chen, Z., Yao, L., Wang, Y., Fan, R., Wang, X., & Shi, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01175-9 · Cited by 432
Detection of prokaryotic mRNA signifies microbial viability and promotes immunity
Sander, L. E., Davis, M. J., Boekschoten, M. V., Amsen, D., Dascher, C. C., Ryffel, B., Swanson, J. A., Müller, M. M., & Blander, J. M. (2011) · Nature · doi:10.1038/nature10072 · Cited by 412
RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges
Yu, A., Choi, Y. H., & Tu, M. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019554 · Cited by 421
Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics
Leppek, K., Byeon, G. W., Kladwang, W., Wayment-Steele, H. K., Kerr, C. H., Xu, A. F., Kim, D. S., Topkar, V. V., Choe, C., Rothschild, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28776-w · Cited by 399
Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics
Leppek, K., Byeon, G. W., Kladwang, W., Wayment-Steele, H. K., Kerr, C. H., Xu, A. F., Kim, D. S., Topkar, V. V., Choe, C., Rothschild, D., et al. (2021) · doi:10.1101/2021.03.29.437587 · Cited by 399
Toll-like receptor 8 senses degradation products of single-stranded RNA
Tanji, H., Ohto, U., Shibata, T., Taoka, M., Yamauchi, Y., Isobe, T., Miyake, K., & Shimizu, T. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2943 · Cited by 404
Materials for non-viral intracellular delivery of messenger RNA therapeutics
Kauffman, K. J., Webber, M. J., & Anderson, D. G. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.032 · Cited by 407
Liang, F., Lindgren, G., Lin, A., Thompson, E. A., Ols, S., Röhss, J., John, S., Hassett, K., Yuzhakov, O., Bahl, K., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.08.006 · Cited by 395
Marshak‐Rothstein, A., & Rifkin, I. R. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104514 · Cited by 394
5-methylcytosine in RNA: detection, enzymatic formation and biological functions
Motorin, Y., Lyko, F., & Helm, M. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp1117 · Cited by 386
Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems
Guan, S., & Rosenecker, J. (2017) · Gene Therapy · doi:10.1038/gt.2017.5 · Cited by 389
mRNA therapeutics in cancer immunotherapy
Beck, J. D., Reidenbach, D., Salomon, N., Sahin, U., Türeci, Ö., Vormehr, M., & Kranz, L. M. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01348-0 · Cited by 385
New Modalities for Challenging Targets in Drug Discovery
Valeur, E., Guéret, S. M., Adihou, H., Gopalakrishnan, R., Lemurell, M., Waldmann, H., Grossmann, T. N., & Plowright, A. T. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201611914 · Cited by 394
Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response
Linares-Fernández, S., Lacroix, C., Exposito, J.-Y., & Verrier, B. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.10.002 · Cited by 376
Laczko, D. I., Hogan, M. J., Toulmin, S. A., Hicks, P. D., Lederer, K., Gaudette, B. T., Castaño, D., Amanat, F., Muramatsu, H., Oguin, T. H., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.019 · Cited by 355
Self-citationActivation of the mammalian immune system by siRNAs
Marques, J. T., & Williams, B. R. G. (2005) · Nature Biotechnology · doi:10.1038/nbt1161 · Cited by 362
mRNA Vaccine Era—Mechanisms, Drug Platform and Clinical Prospection
Xu, S., Yang, K., Li, R., & Zhang, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186582 · Cited by 368
Anderson, B. R., Muramatsu, H., Jha, B. K., Silverman, R. H., Weissman, D., & Kariko, K. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr586 · Cited by 356
RNA modifications in physiology and disease: towards clinical applications
Delaunay, S., Helm, M., & Frye, M. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-023-00645-2 · Cited by 368
A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development
Li, Y., Tenchov, R., Smoot, J., Liu, C., Watkins, S., & Zhou, Q. A. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00120 · Cited by 349
Pardi, N., Secreto, A. J., Shan, X., Debonera, F., Glover, J., Yi, Y., Muramatsu, H., Ni, H., Mui, B. L., Tam, Y. K., et al. (2017) · Nature Communications · doi:10.1038/ncomms14630 · Cited by 352
Self-citationToll‐like receptors 7, 8, and 9: linking innate immunity to autoimmunity
Krieg, A. Μ., & Vollmer, J. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00572.x · Cited by 351
Bacterial recognition by TLR7 in the lysosomes of conventional dendritic cells
Mancuso, G., Gambuzza, M. E., Midiri, A., Biondo, C., Papasergi, S., Akira, S., Teti, G., & Beninati, C. (2009) · Nature Immunology · doi:10.1038/ni.1733 · Cited by 371
Novel approaches for vaccine development
Gebre, M. S., Brito, L. A., Tostanoski, L. H., Edwards, D. K., Carfi, A., & Barouch, D. H. (2021) · Cell · doi:10.1016/j.cell.2021.02.030 · Cited by 347
iRNA-Methyl: Identifying N6-methyladenosine sites using pseudo nucleotide composition
Chen, W., Feng, P., Ding, H., Lin, H., & Chou, K. (2015) · Analytical Biochemistry · doi:10.1016/j.ab.2015.08.021 · Cited by 350
Three decades of messenger RNA vaccine development
Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2019) · Nano Today · doi:10.1016/j.nantod.2019.100766 · Cited by 342
In vivo hematopoietic stem cell modification by mRNA delivery
Breda, L., Papp, T. E., Triebwasser, M. P., Yadegari, A., Fedorky, M. T., Tanaka, N., Abdulmalik, O. Y., Pavani, G., Wang, Y., Grupp, S. A., et al. (2023) · Science · doi:10.1126/science.ade6967 · Cited by 353
Self-citation2′-O-methyl-modified RNAs Act as TLR7 Antagonists
Robbins, M., Judge, A. D., Liang, L. Y., McClintock, K., Yaworski, E., & MacLachlan, I. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300240 · Cited by 339
Lipid-Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Components
Kazemian, P., Yu, S.-Y., Thomson, S. B., Birkenshaw, A., Leavitt, B. R., & Ross, C. J. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00916 · Cited by 363
Nucleic acid delivery for therapeutic applications
Gupta, A., Andresen, J. L., Manan, R. S., & Langer, R. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113834 · Cited by 351
Therapeutic Oligonucleotides: State of the Art
Smith, C. I. E., & Zain, R. (2018) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021050 · Cited by 338
Sensing of Viral Infection and Activation of Innate Immunity by Toll-Like Receptor 3
Vercammen, E., Staal, J., & Beyaert, R. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00022-07 · Cited by 329
Multiple functions of m6A RNA methylation in cancer
Pan, Y., Ma, P., Liu, Y., Li, W., & Shu, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0590-8 · Cited by 315
mRNA vaccines for COVID-19: what, why and how
Park, J. W., Lagniton, P. N. P., Liu, Y., & Xu, R.-H. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59233 · Cited by 321
Regulation of the nucleic acid-sensing Toll-like receptors
Lind, N. A., Rael, V. E., Pestal, K., Liu, B., & Barton, G. M. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00577-0 · Cited by 308
Recent advances in dynamic m 6 A RNA modification
Cao, G., Li, H., Yin, Z., & Flavell, R. A. (2016) · Open Biology · doi:10.1098/rsob.160003 · Cited by 309
COVID-19 mRNA vaccines: Platforms and current developments
Szabó, G. T., Mahiny, A. J., & Vlatkovic, I. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.016 · Cited by 308
Recognition of viral nucleic acids in innate immunity
Yoneyama, M., & Fujita, T. (2009) · Reviews in Medical Virology · doi:10.1002/rmv.633 · Cited by 313
Suzuki, Y., & Ishihara, H. (2021) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2021.100424 · Cited by 323
Freyn, A. W., Ramos da Silva, J., Rosado, V. C., Bliss, C. M., Pine, M., Mui, B. L., Tam, Y. K., Madden, T. D., de Souza Ferreira, L. C., Weissman, D., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.04.018 · Cited by 299
Self-citationTLR7 and TLR8 as targets in cancer therapy
Schön, M., & Schön, M. (2008) · Oncogene · doi:10.1038/sj.onc.1210913 · Cited by 302
Tombácz, I., Laczko, D. I., Shahnawaz, H., Muramatsu, H., Natesan, A., Yadegari, A., Papp, T. E., Alameh, M., Shuvaev, V. V., Mui, B. L., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.06.004 · Cited by 300
Self-citationA double-edged sword of immuno-microenvironment in cardiac homeostasis and injury repair
Sun, K., Li, Y., & Jin, J. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00455-6 · Cited by 311
Hartmann, G. (2017) · Advances in Immunology · doi:10.1016/bs.ai.2016.11.001 · Cited by 285
Elimination of large tumors in mice by mRNA-encoded bispecific antibodies
Stadler, C. R., Bähr-Mahmud, H., Celik, L., Hebich, B., Roth, A. S., Roth, R. P., Karikó, K., Türeci, Ö., & Sahin, U. (2017) · Nature Medicine · doi:10.1038/nm.4356 · Cited by 290
Self-citationAn Update on Self-Amplifying mRNA Vaccine Development
Blakney, A. K., Ip, S., & Geall, A. J. (2021) · Vaccines · doi:10.3390/vaccines9020097 · Cited by 288
Role of nanotechnology behind the success of mRNA vaccines for COVID-19
Khurana, A., Allawadhi, P., Khurana, I., Allwadhi, S., Weiskirchen, R., Banothu, A. K., Chhabra, D., Joshi, K., & Bharani, K. K. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101142 · Cited by 296
Regulation and functions of non-m6A mRNA modifications
Sun, H., Li, K., Liu, C., & Yi, C. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00622-x · Cited by 288
Karikó, K., Muramatsu, H., Keller, J. M., & Weissman, D. (2012) · Molecular Therapy · doi:10.1038/mt.2012.7 · Cited by 282
Self-citationOvercoming the Innate Immune Response to Small Interfering RNA
Judge, A. D., & MacLachlan, I. (2008) · Human Gene Therapy · doi:10.1089/hum.2007.179 · Cited by 281
mRNA-based therapeutics: looking beyond COVID-19 vaccines
Parhiz, H., Atochina‐Vasserman, E. N., & Weissman, D. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02444-3 · Cited by 303
Self-citationDiebold, S. S., Massacrier, C., Akira, S., Paturel, C., Morel, Y., & Sousa, C. R. E. (2006) · European Journal of Immunology · doi:10.1002/eji.200636617 · Cited by 281
TLR8: the forgotten relative revindicated
Cervantes, J., Weinerman, B., Basole, C. P., & Salazar, J. C. (2012) · Cellular and Molecular Immunology · doi:10.1038/cmi.2012.38 · Cited by 283
N6-methyladenosine modification enables viral RNA to escape recognition by RNA sensor RIG-I
Lu, M., Zhang, Z. S., Xue, M., Zhao, B. S., Harder, O. E., Li, A., Liang, X., Gao, T. Z., Xu, Y., Zhou, J., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-019-0653-9 · Cited by 277
Li, N., Hui, H., Bray, B., Gonzalez, G. M., Zeller, M., Anderson, K. G., Knight, R. D., Smith, D. M., Wang, Y., Carlin, A. F., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109091 · Cited by 283
Svitkin, Y. V., Cheng, Y. M., Chakraborty, T., Presnyak, V., John, M., & Sonenberg, N. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx135 · Cited by 278
Savarese, E., Chae, O.-W., Trowitzsch, S., Weber, G., Kastner, B., Akira, S., Wagner, H., Schmid, R. M., Bauer, S., & Krug, A. (2005) · Blood · doi:10.1182/blood-2005-07-2650 · Cited by 273
The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines
Morais, P., Adachi, H., & Yu, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.789427 · Cited by 281
Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis
Robinson, E., MacDonald, K. D., Slaughter, K., McKinney, M., Patel, S., Sun, C., & Sahay, G. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.014 · Cited by 272
Circular RNA vaccine in disease prevention and treatment
Niu, D., Wu, Y., & Lian, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01561-x · Cited by 281
Principles for designing an optimal mRNA lipid nanoparticle vaccine
Kon, E., Elia, U., & Peer, D. (2022) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2021.09.016 · Cited by 269
Vaidyanathan, S., Azizian, K. T., Haque, A. K. M. A., Henderson, J. M., Hendel, A., Shore, S., Antony, J. S., Hogrefe, R. I., Kormann, M. S. D., Porteus, M. H., et al. (2018) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2018.06.010 · Cited by 262
Lipid Nanoparticle–mRNA Formulations for Therapeutic Applications
Wang, C., Zhang, Y., & Dong, Y. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00550 · Cited by 276
RNA therapy: rich history, various applications and unlimited future prospects
Kim, Y. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00757-5 · Cited by 283
From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases
Pilkington, E. H., Suys, E. J. A., Trevaskis, N. L., Wheatley, A. K., Zukancic, D., Algarni, A., Al-Wassiti, H. A., Davis, T. P., Pouton, C. W., Kent, S. J., et al. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.06.023 · Cited by 271
Song, Y., Li, J., & Wu, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01952-8 · Cited by 328
N6-methyladenosine in mRNA disrupts tRNA selection and translation-elongation dynamics
Choi, J., Ieong, K.-W., DeMirci, H., Chen, J., Petrov, A. N., Prabhakar, A., O’Leary, S. E., Dominissini, D., Rechavi, G., Soltis, S. M., et al. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3148 · Cited by 267
Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines
Lutz, J., Lazzaro, S., Habbeddine, M., Schmidt, K. E., Baumhof, P., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., Heidenreich, R., et al. (2017) · npj Vaccines · doi:10.1038/s41541-017-0032-6 · Cited by 257
pRNAm-PC: Predicting N6-methyladenosine sites in RNA sequences via physical–chemical properties
Liu, Z., Xiao, X., Yu, D., Jia, J., Qiu, W., & Chou, K. (2015) · Analytical Biochemistry · doi:10.1016/j.ab.2015.12.017 · Cited by 257
mRNA Vaccines in the COVID-19 Pandemic and Beyond
Hogan, M. J., & Pardi, N. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-042420-112725 · Cited by 260
Fukui, R., Saitoh, S.-I., Matsumoto, F., Kozuka‐Hata, H., Oyama, M., Tabeta, K., Beutler, B., & Miyake, K. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20082316 · Cited by 255
Boosting intracellular delivery of lipid nanoparticle-encapsulated mRNA
Patel, S., Ashwanikumar, N., Robinson, E., DuRoss, A., Sun, C., Murphy-Benenato, K. E., Mihai, C., Almarsson, Ö., & Sahay, G. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b02664 · Cited by 251
Maity, A., & Das, B. (2015) · FEBS Journal · doi:10.1111/febs.13614 · Cited by 253
Ghattas, M., Dwivedi, G., Lavertu, M., & Alameh, M. (2021) · Vaccines · doi:10.3390/vaccines9121490 · Cited by 275
Pollard, C., Rejman, J., De Haes, W., Verrier, B., Van Gulck, E., Naessens, T., De Smedt, S., Bogaert, P., Grooten, J., Vanham, G., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.202 · Cited by 248
Macrophage fumarate hydratase restrains mtRNA-mediated interferon production
Hooftman, A., Peace, C. G., Ryan, D. G., Day, E. A., Yang, M. H., McGettrick, A. F., Yin, M., Montano, E. N., Huo, L., Toller-Kawahisa, J. E., et al. (2023) · Nature · doi:10.1038/s41586-023-05720-6 · Cited by 258
Han, X., Alameh, M., Butowska, K., Knox, J. J., Lundgreen, K. A., Ghattas, M., Gong, N., Xue, L., Xu, Y., Lavertu, M., et al. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01404-4 · Cited by 255
Self-citationRecent Advances in Lipid Nanoparticles and Their Safety Concerns for mRNA Delivery
Wang, J., Ding, Y., Chong, K. C., Cui, M., Cao, Z., Tang, C., Tian, Z., Hu, Y., Zhao, Y., & Jiang, S. (2024) · Vaccines · doi:10.3390/vaccines12101148 · Cited by 270
Regulation and Function of RNA Pseudouridylation in Human Cells
Borchardt, E. K., Martínez, N. M., & Gilbert, W. V. (2020) · Annual Review of Genetics · doi:10.1146/annurev-genet-112618-043830 · Cited by 242
Toll-like receptor 3 (TLR3) regulation mechanisms and roles in antiviral innate immune responses
Chen, Y., Lin, J., Zhao, Y., Ma, X., & Yi, H. (2021) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2000808 · Cited by 260
Biological roles of RNA m5C modification and its implications in Cancer immunotherapy
Song, H., Zhang, J., Liu, B., Xu, J., Cai, B., Yang, H., Straube, J., Yu, X., & Ma, T. (2022) · Biomarker Research · doi:10.1186/s40364-022-00362-8 · Cited by 235
Durbin, A. F., Wang, C., Marcotrigiano, J., & Gehrke, L. (2016) · mBio · doi:10.1128/mbio.00833-16 · Cited by 238
Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability
Zhang, L., More, K. R., Ojha, A., Jackson, C. B., Quinlan, B. D., Li, H., He, W., Farzan, M., Pardi, N., & Choe, H. (2023) · npj Vaccines · doi:10.1038/s41541-023-00751-6 · Cited by 244
Jo, J., Tan, A. T., Ussher, J. E., Sandalova, E., Tang, X.-Z. E., Tan-Garcia, A., To, N., Hong, M. L. W., Chia, A., Gill, U. S., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004210 · Cited by 239
Mechanism of action of mRNA-based vaccines
Iavarone, C., O’hagan, D. T., Yu, D., Delahaye, N. F., & Ulmer, J. B. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1355245 · Cited by 234
Lövgren, T., Eloranta, M., Kastner, B., Wahren‐Herlenius, M., Alm, G. V., & Rönnblom, L. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21893 · Cited by 231
mRNA vaccines for infectious diseases — advances, challenges and opportunities
Pardi, N., & Krammer, F. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01042-y · Cited by 252
Parhiz, H., Shuvaev, V. V., Pardi, N., Khoshnejad, M., Kiseleva, R. Y., Brenner, J. S., Uhler, T., Tuyishime, S., Mui, B. L., Tam, Y. K., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.015 · Cited by 233
Self-citationAn RNA toolbox for cancer immunotherapy
Pastor, F., Berraondo, P., Etxeberria, I., Frederick, J., Sahin, U., Gilboa, E., & Melero, I. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.132 · Cited by 229
Cap 1 Messenger RNA Synthesis with Co‐transcriptional CleanCap ® Analog by In Vitro Transcription
Henderson, J. M., Ujita, A., Hill, E., Yousif‐Rosales, S., Smith, C., Ko, N., McReynolds, T., Cabral, C. R., Escamilla‐Powers, J. R., & Houston, M. E. (2021) · Current Protocols · doi:10.1002/cpz1.39 · Cited by 231
Strategies to reduce the risks of mRNA drug and vaccine toxicity
Bitounis, D., Jacquinet, E., Rogers, M. A., & Amiji, M. M. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00859-3 · Cited by 242
Epitranscriptomic Enhancement of Influenza A Virus Gene Expression and Replication
Courtney, D., Kennedy, E. M., Dumm, R. E., Bogerd, H. P., Tsai, K., Heaton, N. S., & Cullen, B. R. (2017) · Cell Host & Microbe · doi:10.1016/j.chom.2017.08.004 · Cited by 229
RNA Interference-Induced Innate Immunity, Off-Target Effect, or Immune Adjuvant?
Meng, Z., & Lu, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00331 · Cited by 226
Weissman, D. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.973859 · Cited by 228
Self-citationTregoning, J. S., Brown, E. S., Cheeseman, H. M., Flight, K. E., Higham, S. L., Lemm, N.-M., Pierce, B. F., Stirling, D. C., Wang, Z., & Pollock, K. M. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13517 · Cited by 226
Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives
Gómez-Aguado, I., Rodríguez-Castejón, J., Vicente-Pascual, M., Rodríguez‐Gascón, A., Solinís, M. Á., & del Pozo‐Rodríguez, A. (2020) · Nanomaterials · doi:10.3390/nano10020364 · Cited by 229
Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening
Guimarães, P. P. G., Zhang, R., Spektor, R., Tan, M., Chung, A., Billingsley, M. M., El-Mayta, R. D., Riley, R., Wang, L., Wilson, J. M., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.10.028 · Cited by 224
Metadata
- Authors
- Karikó, K., Buckstein, M., Ni, H., & Weissman, D.
- Affiliations
- University of Pennsylvania (US)
- Corresponding author
- Karikó, Katalin
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2005-08
- Volume
- 23
- Issue
- 2
- Pages
- 165-175
- ISSN
- 1074-7613 (ISSN-L)
- OpenAlex
- W2025980739
- Cited by
- 2,728
- References
- 35
- Citations by year
- 2026: 319 · 2025: 387 · 2024: 355 · 2023: 323 · 2022: 296 · 2021: 267 · 2020: 86 · 2019: 76 · 2018: 80 · 2017: 58 · 2016: 66 · 2015: 58 · 2014: 48 · 2013: 46 · 2012: 39
- FWCI
- 13.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Immunity (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (AI-50484, AI 060505, R01AI050484, R01AI060505)
- National Institute of Dental and Craniofacial Research (R01DE014825, DE 14825)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
- Keywords
- Toll-like receptors, RNA recognition, nucleoside modification, TLR3, TLR7, TLR8, m5C, N6-methyladenosine, pseudouridine, dendritic cells, innate immunity, CpG methylation, mitochondrial RNA, bacterial RNA, RNA evolution, cytokine expression
- MeSH terms
- CD83 Antigen, Cell Line, Dendritic Cells, HLA-DR Antigens, Humans, Immunoglobulins, Membrane Glycoproteins, Nucleosides, Phosphatidylethanolamines, Receptors, Cell Surface, RNA, Signal Transduction, Biomarkers, Antigens, CD, Cytokines, Evolution, Molecular, Toll-Like Receptors, Toll-Like Receptor 3, Toll-Like Receptor 7, Toll-Like Receptor 8
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
